MacroGenics Inc. (NASDAQ: MGNX): Can A Stock That’s Down -79.25% YTD Still Be Considered In Loss Territory? – Marketing Sentinel
Home  »  Technologies   »  MacroGenics Inc. (NASDAQ: MGNX): Can A Stock That...

MacroGenics Inc. (NASDAQ: MGNX): Can A Stock That’s Down -79.25% YTD Still Be Considered In Loss Territory?

During the last session, MacroGenics Inc. (NASDAQ:MGNX)’s traded shares were 1.2 million, with the beta value of the company hitting 2.22. At the end of the trading day, the stock’s price was $3.33, reflecting an intraday gain of 3.10% or $0.1. The 52-week high for the MGNX share is $29.16, that puts it down -775.68 from that peak though still a striking 36.04% gain since the share price plummeted to a 52-week low of $2.13. The company’s market capitalization is $199.80M, and the average trade volume was 1.10 million shares over the past three months.

MacroGenics Inc. (NASDAQ:MGNX) trade information

MacroGenics Inc. (MGNX) registered a 3.10% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.10% in intraday trading to $3.33 this Thursday, 06/23/22, hitting a weekly high. The stock’s 5-day price performance is 41.70%, and it has moved by -15.91% in 30 days. Based on these gigs, the overall price performance for the year is -86.98%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

MacroGenics Inc. (MGNX) estimates and forecasts

Statistics show that MacroGenics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. MacroGenics Inc. (MGNX) shares have gone down -80.26% during the last six months, with a year-to-date growth rate less than the industry average at 6.53% against 8.40. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -45.50% this quarter and then jump 36.00% in the quarter after that. In the rating firms’ projections, revenue will increase 6.70% compared to the previous financial year.

Revenue for the current quarter is expected to be $14.06 million as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to $48.26 million by the end of Sep 2022.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -14.80%. While earnings are projected to return -36.30% in 2022.

MGNX Dividends

MacroGenics Inc. is due to release its next quarterly earnings between April 27 and May 02. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

MacroGenics Inc. (NASDAQ:MGNX)’s Major holders

MacroGenics Inc. insiders own 2.54% of total outstanding shares while institutional holders control 96.51%, with the float percentage being 99.02%. Bellevue Group AG is the largest shareholder of the company, while 226 institutions own stock in it. As of Dec 30, 2021, the company held over 8.56 million shares (or 13.96% of all shares), a total value of $137.4 million in shares.

The next largest institutional holding, with 6.1 million shares, is of RA Capital Management, L.P.’s that is approximately 9.95% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $97.96 million.

Also, the Mutual Funds coming in first place with the largest holdings of MacroGenics Inc. (MGNX) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Wasatch Ultra Growth Fund. Data provided on Jan 30, 2022 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 2.01 million shares. This amounts to just over 3.28 percent of the company’s overall shares, with a $24.82 million market value. The same data shows that the other fund manager holds slightly less at 1.74 million, or about 2.83% of the stock, which is worth about $15.3 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]